Analyzing the key gene expression and prognostics values for acute myeloid leukemia

Area of Science:

• Genomics
• Oncology
• Molecular Biology

Background:

• Acute myeloid leukemia (AML) is a significant hematologic malignancy.
• Whole-genome sequencing has identified numerous mutations in AML, but their functional and prognostic implications remain incompletely understood.

Purpose of the Study:

• To comprehensively analyze the expression levels, functions, and prognostic values of mutated genes in AML.
• To identify potential therapeutic targets and drug sensitivities associated with these mutations.

Main Methods:

• Utilized the Cancer Virtual Cohort Discovery Analysis Platform (CVCDAP) for analyzing mutated genes.
• Employed Gene Expression Profiling Interactive Analysis (GEPIA) and UALCAN datasets to assess gene expression and patient prognosis.
• Performed functional enrichment analysis using Metascape and pathway analysis using GSCALite.

Main Results:

• Identified top mutated genes in AML, including FLT3, HPS3, ABCA6, PCLO, and SLIT2.
• Observed significant differential expression of genes such as NPM1, GABRB3, TP53, DNMT3A, HPS3, FLT3, SENP6, and RUNX1.
• FLT3 and PCLO overexpression correlated with poor prognosis, while SLIT3 and HPS3 showed protective effects. Identified drug sensitivities for FLT3, DNMT3A, IDH2, RUNX1, and TP53.

Conclusions:

• Specific gene overexpression (FLT3, ABCA6, PCLO) indicates poor AML prognosis, while others (SLIT3, HPS3) are protective.
• Identified several actionable drug targets and small molecules for treating AML based on gene mutation profiles.